The impact of vildagliptin as an add‐on therapy on matrix metalloproteinase‐14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non‐alcoholic steatohepatitis: A randomized controlled trial
Authors' conclusion
Administration of vildagliptin for adolescents with T1DM and NASH improved glycaemic control, dyslipidaemia and MMP-14 levels and decreased liver stiffness and CIMT; hence, reducing subclinical atherosclerosis and disease progression.
Study context
- Population
- Adolescents with T1D and non-alcoholic steatohepatitis (NASH)
- Participants
- 60 adolescents
- Comparison
- Oral vildagliptin add-on vs no vildagliptin
Primary result
As reported in the abstract
HbA1c, lipid profile, hepatic steatosis index, TyG index, MMP-14, CIMT, liver stiffness and CAP · 6 months
- Significantly lower HbA1c, lipid profile, hepatic steatosis index, triglyceride glucose (TyG) index and MMP-14 with vildagliptin
- p < 0.001
- Carotid intima media thickness (CIMT), liver stiffness and controlled attenuation parameter (CAP) significantly decreased post-therapy vs baseline and vs control
- p < 0.001
Further findings
Elevated liver stiffness ≥7 kPa (F2 stage or higher) at baseline
- Patients with elevated liver stiffness ≥7 kPa
- 12 (20%)
Correlates of baseline MMP-14
- MMP-14 positively correlated with insulin dose
- P = 0.016
- MMP-14 positively correlated with TG, TyG index, CIMT, liver stiffness and CAP
- P < 0.001 for all
Safety
- Vildagliptin was safe and well-tolerated
Original publication
The impact of vildagliptin as an add‐on therapy on matrix metalloproteinase‐14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non‐alcoholic steatohepatitis: A randomized controlled trial. Diabetes Obes Metab. Published 24 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →